Atopic Dermatitis: Ziarco Hopes Oral Therapy Will Trump Injectable Biologics

UK biotech Ziarco’s orally active histamine H4-antagonist shows potential in atopic dermatitis in proof-of-concept studies, and the firm may seek capital for further studies before it is Phase III ready.